Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.41 |
| ▸ | IDO1 | P14902 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | PSEN1 | P49768 | 5/20 | 0.36 |
| ▸ | PSEN2 | P49810 | 5/20 | 0.36 |
| ▸ | APH1B | Q8WW43 | 5/20 | 0.36 |
| ▸ | NCSTN | Q92542 | 5/20 | 0.36 |
| ▸ | APH1A | Q96BI3 | 5/20 | 0.36 |
| ▸ | PSENEN | Q9NZ42 | 5/20 | 0.36 |
| ▸ | ACHE | P22303 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20095992 | 1.00 | CA1 (0.41) | CA1CA2IDO1ALDH1A1PSEN1 | |
| SCHEMBL1415538 | 0.83 | IDO1 (0.48) | CA1CA2IDO1ALDH1A1PSEN1 | |
| SCHEMBL5375159 | 0.82 | HDAC3 (0.38) | CA1CA2 | |
| SCHEMBL2736641 | 0.82 | HDAC3 (0.38) | CA1CA2 | |
| SCHEMBL13850672 | 0.82 | HDAC3 (0.38) | CA1CA2 | |
| SCHEMBL2736644 | 0.82 | HDAC3 (0.38) | CA1CA2 | |
| SCHEMBL8068154 | 0.79 | NAE1 (0.40) | — | |
| SCHEMBL8057823 | 0.79 | NAE1 (0.40) | — | |
| SCHEMBL18995717 | 0.78 | PDPK1 (0.39) | CA1CA2ALDH1A1 | |
| SCHEMBL5837425 | 0.77 | CA1 (0.35) | CA1CA2ALDH1A1PSEN1PSEN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2020-04-16 | — | — | US | disclosed |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | GENENTECH, INC. (US) | 2019-10-29 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | GENENTECH, INC. (US) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200115354-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | CA1 1419/4885CA2 691/4885IDO1 2327/4885 |
| US-10457654-B2 | Therapeutic compounds and methods of use thereof | NPY5R, REN, F12 | CA1 1419/4885CA2 691/4885IDO1 2327/4885 |
| US-20180105504-A1 | THERAPEUTIC COMPOUNDS AND METHODS OF USE THEREOF | NPY5R, REN, F12 | CA1 1455/4885CA2 702/4885IDO1 2338/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.